ALT Altimmune, Inc.
USHealthcareAs of 2026-08-24
Why ALT matters now
Altimmune, Inc. (ALT) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.11 with +0.00% on the session and $604.8M in market capitalization; recent performance reads 1-month -1.46% and YTD -25.21%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-22.6M, and EPS of $-0.18. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -30.2%.
The latest indexable market news headline is "Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $11.25; recent insider activity includes SAYARE MITCHEL filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.18
P/S
6619.30
EV/EBITDA
-2.00
DCF Value
$0.08
FCF Yield
-30.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-41519.4%
Operating Margin
-269216.7%
Net Margin
-253002.8%
ROE
-42.6%
ROA
-27.1%
ROIC
-29.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-22.6M | $-0.18 |
| Q4 2025 | $26.0K | $-27.4M | $-0.27 |
| FY 2025 | $41.0K | $-88.1M | $-1.00 |
| Q3 2025 | $5.0K | $-19.0M | $-0.21 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$11.25
Target (Median)
$11.25
Target Range
$2.50 - $20.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.23
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.